Citizens reiterates its "Buy" rating on Ideaya Biosciences stock following positive trial data for its novel PKC inhibitor, IDE196, which is being developed for uveal melanoma and other solid tumors.
Citizens has maintained its positive stance on Ideaya Biosciences, reaffirming a "Buy" rating. This decision is underpinned by encouraging clinical trial results for IDE196, a promising new treatment candidate targeting specific cancers.
Citizens has maintained its positive stance on Ideaya Biosciences, reaffirming a "Buy" rating. This decision is underpinned by encouraging clinical trial results for IDE196, a promising new treatment candidate targeting specific cancers.
Pick the topics you care about. Get only what matters, on your cadence.
Waiting for the stock market crash? Why it may never come and what it means for missed returnshome.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.